To this end, human lung carcinoma A549 and cervical cancer HeLa cells were treated with 1 μM AZD8055 (an inhibitor of mTOR kinase activity, and thus a control that impairs mTOR signalling) or 200 nM BafA (a commonly used concentration [22] and within the range recommended by manufacturers) for 6 or 24 h. The gene discussed is MTOR; the disease is cervical carcinoma.